Clinical Trials Logo
  1. Home
  2. Bulimia Nervosa
  3. NCT03338387

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

Bulimia Nervosa Clinical Trial

Official title:
Acipimox Administration Together With Short-Term Exercise Exerts A Co-Feedback of Growth Hormone, Pancreatic Polypeptide, Peptide YY and Leptin on Ghrelin in Young Bulimic Czech Women: A Randomized Study

Clinical Trial Summary

This study evaluates the addition of Acipimox or placebo to exercise on growth hormone release and ghrelin secretion in bulimic patients and in healthy women. Two groups of participants will receive Acipimox together with exercise versus identical placebo with exercise.

Clinical Trial Description

Acipimox and exercise each increase growth hormone release, but they do so by different mechanisms. Acipimox is an anti-lipolytic drug and increases growth hormone release by decreasing free fatty acids levels and that Acipimox may exert to a negative feedback of growth hormone on ghrelin. Physical exercise is a potent physiological stimulus for growth hormone release. As ghrelin has a stimulatory effect on growth hormone secretion, growth hormone may inhibit circulating ghrelin levels via a feedback loop. Growth hormone stimulates lipolysis and resultant free fatty acids may suppress ghrelin secretion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03338387
Study type Interventional
Source Charles University, Czech Republic
Contact
Status Enrolling by invitation
Phase Phase 2
Start date May 6, 2003
Completion date December 20, 2023
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT02978742 - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder N/A
Withdrawn NCT00988481 - Topiramate Augmentation in Bulimia Nervosa Partial Responders Phase 4
Completed NCT00184301 - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder. N/A
Completed NCT00522769 - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Phase 1/Phase 2
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Recruiting NCT04409457 - Self-Control in Bulimia Nervosa N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Recruiting NCT05937243 - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating N/A
Recruiting NCT05862389 - Study on the Mechanism of Eating Disorder
Recruiting NCT05728021 - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa N/A
Completed NCT03781921 - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed NCT02553824 - FDA Approved Medication to Reduce Binge Eating and/or Purging Phase 1
Recruiting NCT05575960 - Interpersonal Psychotherapy for Adolescents and Young Adults N/A
Terminated NCT04041024 - Decision-making and Risk-taking in Bulimia N/A
Completed NCT04265131 - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome? N/A
Recruiting NCT02960152 - Periodontal Impact of Eating Disorders (the PERIOED Study) N/A
Completed NCT00916071 - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders N/A
Terminated NCT00308776 - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa N/A